drug
TICAGRELOR
Marketedupdated 3mo agoby Hisun Pharmaceutical USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(9)
approval · 9
Apr 7, 2020
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
May 1, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
May 2, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Oct 28, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Oct 28, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Oct 28, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Oct 28, 2025
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Feb 6, 2026
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Mar 24, 2026
approval
TICAGRELOR — FDA approval
TICAGRELOR
→
Trials studying TICAGRELOR
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- N/AThromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
- phase1Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.
- phase1Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
- phase3DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
- phase3TADCLOT- a Double Blind Randomized Controlled Trial
- phase1A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
- phase1A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 17, 2030
~3.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 27, 2036patentUS 10300065*PED
- Jul 27, 2036patentUS 10300065*PED
- Jan 27, 2036method-of-use (U-2542)US 10300065
- Jan 27, 2036method-of-use (U-2542)US 10300065
- Oct 17, 2030patentUS 8425934*PED4.2y
- Oct 17, 2030patentUS 8425934*PED4.2y
- Apr 17, 2030formulationUS 84259343.7y
- Apr 17, 2030formulationUS 84259343.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that